Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam

References

• Afsar A, Lee C, Riddick DS. (1996). Modulation of the expression on constitutive rat hepatic cytochrome P450 isozymes by 5-fluorouracil. Can J Physiol Pharmacol 74:150–6.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Chu E, Allegra C. (2019). Therapeutic drug monitoring in oncology: International association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther. 105:598–613.
   PubMed Web of Science ®Google Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–54.
   PubMed Web of Science ®Google Scholar
• Brown HS, Chadwick A, Houston JB. (2007). Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 35:2119–26.
   PubMed Web of Science ®Google Scholar
• Chovan JP, Ring SC, Yu E, et al. (2007). Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica 37:459–73.
   PubMed Web of Science ®Google Scholar
• De Martin S, Gabbia D, Albertin G, et al. (2014). Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat. Drug Metab Dispos 42:1617–26.
   PubMed Web of Science ®Google Scholar
• Dolnick BJ, Pink JJ. (1985). Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J Biol Chem 260:3006–14.
   PubMed Web of Science ®Google Scholar
• Ervine CM, Matthew DE, Brennan B, et al. (1996). Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metab Dispos 24:211–5.
   PubMed Web of Science ®Google Scholar
• Franke RM, Baker SD, Mathijssen RH, et al. (2008). Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin Pharmacol Ther 84:704–9.
   PubMed Web of Science ®Google Scholar
• Fukuno S, Nagai K, Kasahara K, et al. (2018). Altered tolbutamide pharmacokinetics by a decrease in hepatic expression of CYP2C6/11 in rats pretreated with 5-fluorouracil. Xenobiotica 48:53–9.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Sadrieh N, Reik L, et al. (1996a). Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Arch Biochem Biophys 332:153–62.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Satoh H, Thomas PE, et al. (1996b). Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450 . Drug Metab Dispos 24:940–7.
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, et al. (1994). Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643–53.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2007). Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163–8.
   PubMed Web of Science ®Google Scholar
• He F, Zhang W, Zeng C, et al. (2015). Mechanism of action of panaxytriol on midazolam 1'-hydroxylation and 4-hydroxylation mediated by CYP3A in liver microsomes and rat primary hepatocytes. Biol Pharm Bull 38:1470–7.
   PubMed Web of Science ®Google Scholar
• Heizmann P, Ziegler WH. (1981). Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220–3.
   PubMed Web of Science ®Google Scholar
• Jin YY, Chen QJ, Xu K, et al. (2016). Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. Mol Cell Biochem 422:161–70.
   PubMed Web of Science ®Google Scholar
• Kajikawa N, Doi M, Kusaba J-i, Aiba T. (2014). Effect of carrageenan-induced acute peripheral inflammation on the pharmacokinetics and hepatic metabolism of midazolam in rats. Drug Metab Pharmacokinet 29:400–6.
   PubMed Web of Science ®Google Scholar
• Konishi H, Yoshimoto T, Morita K, et al. (2003). Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. J Pharm Pharmacol 55:143–9.
   PubMed Web of Science ®Google Scholar
• Kotegawa T, Laurijssens BE, Von Moltke LL, et al. (2002). In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228–37.
   PubMed Web of Science ®Google Scholar
• Leon JA, Britt JM, Hopp RH, et al. (1990). Effects of fluorouracil and fluorouridine on protein synthesis in rabbit retina. Invest Ophthalmol Vis Sci 31:1709–16.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–8.
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391–6.
   PubMed Web of Science ®Google Scholar
• Marin-Vicente C, Lyutvinskiy Y, Romans Fuertes P, et al. (2013). The effects of 5-fluorouracil on the proteome of colon cancer cells. J Proteome Res 12:1969–79.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Sludden J, Hardy SC, et al. (1998). Autoregulation of 5-fluorouracil metabolism. Eur J Cancer 34:1623–7.
   PubMed Web of Science ®Google Scholar
• Mojardín L, Botet J, Quintales L, et al. (2013). New insights into the RNA-based mechanism of action of the anticancer drug 5'-fluorouracil in eukaryotic cells. PLoS One 8:e78172.
   PubMed Web of Science ®Google Scholar
• Mokhtari RB, Homayouni TS, Baluch N, et al. (2017). Combination therapy in combating cancer. Oncotarget 8:38022–43.
   PubMedGoogle Scholar
• Moore JT, Kliewer SA. (2000). Use of the nuclear receptor PXR to predict drug interactions. Toxicology 153:1–10.
   PubMed Web of Science ®Google Scholar
• Nagai K, Suzuki S, Yamamura A, et al. (2015). Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol. Biopharm Drug Dispos 36:174–82.
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA. (2003). Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol 59:407–9.
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. (2008). Dose translation from animal to human studies revisited. Faseb J 22:659–61.
   PubMed Web of Science ®Google Scholar
• Sandborg RR, Siegel IA. (1990). Effects of 5-fluorouracil on protein synthesis and secretion of the rat parotid gland. Arch Oral Biol 35:991–1001.
   PubMed Web of Science ®Google Scholar
• Shaw AA, Hall SD, Franklin MR, et al. (2002). The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos 30:177–82.
   PubMed Web of Science ®Google Scholar
• Shimada M, Nagata K, Murayama N, et al. (1989). Role of growth hormone in modulating the constitutive and phenobarbital-induced levels of two P-450(6)beta (testosterone 6 beta-hydroxylase) mRNAs in rat livers . J Biochem 106:1030–4.
   PubMed Web of Science ®Google Scholar
• Sinz MW. (2013). Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development. Drug Metab Rev 45:3–14.
   PubMed Web of Science ®Google Scholar
• Souidi M, Gueguen Y, Linard C, et al. (2005). In vivo effects of chronic contamination with depleted uranium on CYP3A and associated nuclear receptors PXR and CAR in the rat. Toxicology 214:113–22.
   PubMed Web of Science ®Google Scholar
• Stupans I, Richards DA, McClure MT. (1995). Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica 25:1–8.
   PubMed Web of Science ®Google Scholar
• Tang W, Stearns RA. (2001). Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185–98.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD, Podoll TD, et al. (1994). Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271:549–56.
   PubMed Web of Science ®Google Scholar
• Tian X, Cheng ZY, Jin H, et al. (2013). Inhibitory effects of baicalin on the expression and activity of CYP3A induce the pharmacokinetic changes of midazolam in rats. Evid Based Complement Alternat Med 2013:179643.
   PubMedGoogle Scholar
• Tirumani SH, Kim KW, Nishino M, et al. (2014). Update on the role of imaging in management of metastatic colorectal cancer. Radiographics 34:1908–28.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Satoh T, Tsuji A, et al. (2012). First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study. Cancer Sci 103:1502–7.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen RW, Swart EL, Boven E, et al. (2011). Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 22:2334–41.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Takakura Y. (2004). Analysis methods and recent advances in nonlinear pharmacokinetics from in vitro through in loci to in vivo. Drug Metab Pharmacokinet 19:397–406.
   PubMedGoogle Scholar
• Yoshisue K, Nagayama S, Shindo T, et al. (2001). Effects of 5-fluorouracil on the drug-metabolizing enzymes of the small intestine and the consequent drug interaction with nifedipine in rats. J Pharmacol Exp Ther 297:1166–75.
   PubMed Web of Science ®Google Scholar
• Yu L, Lu S, Zhao N, et al. (2008). Male-specific induction of CYP3A2 in rats by zolmitriptan. J Pharm Pharmacol 60:1601–7.
   PubMed Web of Science ®Google Scholar